SB5594 aims to enhance access to biosimilar medicines by modifying prescription drug utilization management and reimbursement policies.

SB5594 revises policies to facilitate the use of biosimilar medicines, which are FDA-approved alternatives to biologic drugs. The bill mandates that pharmacists may substitute a biosimilar or interchangeable biological product for a prescribed biologic drug unless the prescriber explicitly indicates otherwise. It also requires health carriers to cover emergency drug supplies if a provider deems it necessary. Additionally, the bill establishes criteria for approving or denying prescription drug utilization management exceptions, ensuring timely responses and clear communication with providers.

SB5594 aims to enhance access to biosimilar medicines by modifying prescription drug utilization management and reimbursement policies.

SB5594 revises policies to facilitate the use of biosimilar medicines, which are FDA-approved alternatives to biologic drugs. The bill mandates that pharmacists may substitute a biosimilar or interchangeable biological product for a prescribed biologic drug unless the prescriber explicitly indicates otherwise. It also requires health carriers to cover emergency drug supplies if a provider deems it necessary. Additionally, the bill establishes criteria for approving or denying prescription drug utilization management exceptions, ensuring timely responses and clear communication with providers.